Dark Blue Therapeutics
Health
· Headquartered in United Kingdom 🇬🇧
Website
HQ Country
🇬🇧 United Kingdom
LinkedIn
Careers
No public jobs page
Track Dark Blue Therapeutics
— get Health deals in free daily digest
Overview
UK-based Dark Blue Therapeutics, a biotech company focused on precision oncology, has been acquired by US biotech giant Amgen in a deal valued at up to €718 million ($840 million). The acquisition aims to accelerate the development of Dark Blue's lead candidate, dbt-3757, a first-in-class therapy for leukemia. Key investors include Oxford Science Enterprises, Bristol Myers Squibb, and Evotec, highlighting the strong investment landscape in oncology.
Products
Loading...
Synthesising company profile
Reading press coverage to extract founders, customers, traction signals and competitive positioning…
Recent Announcements
Investors: Oxford Science Enterprises, Bristol Myers Squibb, Evotec
UK-based Dark Blue Therapeutics, a biotech company focused on precision oncology, has been acquired by US biotech giant Amgen in a deal valued at up to €718 million ($840 million). The acquisition aims to accelerate the development of Dark Blue's lead candidate, dbt-3757, a first-in-class therapy for leukemia. Key investors include Oxford Science Enterprises, Bristol Myers Squibb, and Evotec, highlighting the strong investment landscape in oncology.
More Health Deals
Market Map
View thousands of companies by category in our market map:
